C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
6.8 ^USD	+5.43%		+5.75%	+20.35%

May. 09	Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating	MT
May. 08	C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates	MT

C4 Therapeutics, Inc. Announces Resignation of Elena Prokupets as Director and Member of the Audit, Compensation and Nominating and Corporate Governance Committees

March 16, 2022 at 04:16 pm EDT

C4 Therapeutics, Inc. announced on March 10, 2022, Elena Prokupets, Ph.D., resigned as a director and as a member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board. The resignation was not due to any disagreements with the Company on any matter relating to the company's operations, policies or practices.

Latest news about C4 Therapeutics, Inc.

Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating	May. 09	MT
C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates	May. 08	MT
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	Apr. 08	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer	Mar. 04	MT
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins	Mar. 04	CI
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $8 From $1, Maintains Equal-Weight Rating	Feb. 26	MT
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
North American Morning Briefing : Microsoft Kicks -2-	Jan. 30	DJ
C4 Therapeutics Shares Jump After JPMorgan Upgrade	Jan. 29	MT
JPMorgan Upgrades C4 Therapeutics to Neutral From Underweight, Price Target is $6	Jan. 29	MT
Transcript : C4 Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:00 AM	Jan. 11
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	Jan. 03	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
North American Morning Briefing : Dow Set For New -2-	Dec. 14	DJ
Top Midday Gainers	Dec. 13	MT
Sector Update: Health Care Stocks Flat Premarket Wednesday	Dec. 13	MT
Stifel Upgrades C4 Therapeutics to Buy From Hold, Raises Price Target to $12 From $2	Dec. 13	MT
C4 Therapeutics Flags 'Promising' Early Data in Trial of Multiple Myeloma, Non-Hodgkin's Lymphomas Treatment	Dec. 13	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 12	MT
C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma	Dec. 12	CI
Sector Update: Health Care	Dec. 12	MT
Top Midday Gainers	Dec. 12	MT
Transcript : C4 Therapeutics, Inc. - Special Call	Dec. 12

Chart C4 Therapeutics, Inc.

Duration

Period

More charts

Company Profile

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patientsâ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the bodyâs natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - European Society for Medical Oncology Congress

More about the company

Income Statement Evolution

More financial data

Ratings for C4 Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.45 USD

Average target price

17.22 USD

Spread / Average Target

+167.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
C4 THERAPEUTICS, INC.	+20.35%	444M
MODERNA, INC.	+23.37%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-0.94%	41.52B
CELLTRION, INC.	-5.86%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.29%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.26B
BIO-TECHNE CORPORATION	+3.20%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	12.08B
MEDPACE HOLDINGS, INC.	+30.23%	11.98B

Other Biotechnology & Medical Research